NEWARK, Calif., May 29, 2019 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX) today announced the appointment of
Don Kalkofen as Chief Financial
Officer. Mr. Kalkofen brings over 29 years of finance and corporate
management experience to the company.
"Mr. Kalkofen brings a broad range of experience with corporate
management and financial oversight to Protagonist," commented
Dinesh V. Patel, Ph.D., Protagonist
President and Chief Executive Officer. "With deep leadership
experience working with public companies and a strong history of
success in both in-house and consulting roles, we are pleased to
have Mr. Kalkofen join the company as we continue to strengthen our
foundation for long term growth. Mr. Kalkofen has demonstrated
expertise in key areas of finance including international
intellectual property transactions, tax credits, revenue
recognition and potential financings in his recent advisory work
with Protagonist. We look forward to benefiting from the skills and
efficiencies that he will bring to the company as an integral
member of the senior executive team."
Prior to joining the Protagonist Therapeutics team, Mr. Kalkofen
served in an advisory role as Senior Advisor, Finance, to the
Company. Mr. Kalkofen's experience includes over fifteen years as a
Chief Financial Officer in both public and private companies. Mr.
Kalkofen has had an extensive consulting career and held positions
including the Chief Financial Officer at App Annie; Assistant
Controller at Align Technology; Vice President of Finance at
Simplifier Corporation and Chief Financial Officer of Innovative
Bank. Earlier in his career, Mr. Kalkofen served as the Chief
Financial Officer for West Coast Bancorp, Pinnacle Bank and
DecisionPoint Applications. He started his career at
PricewaterhouseCoopers, received his B.A. in accounting from
Washington State University, and is a
Certified Public Accountant and Certified Global Management
Accountant.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to transform existing
treatment paradigms for patients with significant unmet medical
needs. PTG-300 is an injectable hepcidin mimetic for the potential
treatment of anemia and iron overload related rare blood diseases
with an initial focus on beta-thalassemia. PTG-200 is an oral,
gut-restricted interleukin-23 receptor antagonist in development
for the treatment of inflammatory bowel disease. The Company has a
worldwide license and collaboration agreement with Janssen Biotech
for the clinical development of PTG-200. PN-943 is an oral,
gut-restricted alpha-4-beta-7 integrin antagonist peptide in
development for the treatment of inflammatory bowel disease.
Protagonist is headquartered in Newark, California, with pre-clinical and
clinical staff in California and
discovery operations in both California and Brisbane, Queensland, Australia. For further
information, please visit http://www.protagonist-inc.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-appoints-don-kalkofen-as-chief-financial-officer-300858602.html
SOURCE Protagonist Therapeutics, Inc.